OnKure Secures $150M for Next-Gen Selective Cancer Therapies

BOULDER, Colo. – March 27, 2026 – OnKure Therapeutics has secured a significant $150 million in an oversubscribed private placement, a move that signals strong investor confidence in the biopharmaceutical company's pivot towards a new generation of precision cancer drugs. The financing, led by new investor Access Biotechnology, is set to fuel the development of two promising candidates designed to treat breast cancer and rare vascular anomalies with unprecedented selectivity.

The capital injection provides OnKure with a multi-year cash runway extending into 2029, empowering the company to advance its next-generation PI3Kα pan-mutant selective inhibitors. These therapies, OKI-345 for breast cancer and OKI-355 for vascular anomalies, represent a strategic shift for the company, which aims to file Investigational New Drug (IND) applications for both programs in the first half of 2027.

“This transformational financing enables us to advance the development strategy for our next‑generation PI3Kα pan‑mutant selective inhibitor candidates, which represent a defining phase of our mutation‑selective strategy,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure. “We appreciate the significant commitment by the participating specialist biotech investors who believe in the potential of our PI3Ka pan-mutant portfolio.”

A Strategic Pivot to Precision

The announcement also marks a calculated pivot in OnKure's clinical strategy. The company revealed it will not pursue further independent development of its first-generation candidate, OKI-219, at this time. This decision comes despite encouraging preliminary safety and tolerability data from the ongoing PIKture-01 trial. Enrollment for key arms of that study has been completed, and mature data is expected by the end of the year.

Instead of pushing forward with OKI-219, OnKure is channeling its resources and the insights gained from that trial into its more advanced pan-mutant programs. Dr. Saccomano emphasized this point, stating, “We believe the clinical experience generated from the PIKture‑01 trial provided important validation of our approach... These insights directly informed the design of our pan‑mutant programs, defining the high bar attributes of our molecules.”

This strategic deprioritization is a bold move, reflecting a deep confidence in the superiority of the next-generation platform. By focusing on candidates designed from the ground up to be highly selective, OnKure is betting on a future where efficacy is not compromised by debilitating side effects.

The Promise of Selective Inhibition

The scientific foundation of OnKure’s new strategy lies in overcoming a major hurdle that has plagued an entire class of cancer drugs. The PI3Kα pathway is a critical signaling route for cell growth, and mutations in the PIK3CA gene are one of the most common drivers of cancer, found in approximately 40% of patients with HR+/HER2- breast cancer.

While first-generation PI3Kα inhibitors like alpelisib have been approved, their utility is often limited by significant “class-limiting toxicities.” Because these drugs inhibit both the mutated (cancer-driving) and wild-type (healthy) forms of the PI3Kα protein, they frequently cause severe side effects, including hyperglycemia, rash, and diarrhea. These toxicities can force dose reductions or treatment discontinuation, limiting the drug's overall effectiveness.

OnKure’s next-generation candidates, OKI-345 and OKI-355, are engineered to be different. Described as “pan-mutant selective,” they are designed to bind to a novel allosteric pocket on the PI3Kα protein, allowing them to specifically inhibit the mutant forms while sparing the wild-type version. This approach promises a much wider therapeutic window, potentially enabling higher, more sustained target coverage with significantly fewer side effects. This improved tolerability could also make the drugs more effective in combination with other standard-of-care cancer therapies.

The field is highly competitive, with companies like Relay Therapeutics and Novartis also pursuing more selective PI3Kα inhibitors, indicating a broader industry shift toward this more sophisticated approach. OnKure's progress places it among the key innovators in this critical area of oncology.

Beyond Cancer: Hope for a Rare Disease

While breast cancer is a primary focus with OKI-345, OnKure is also breaking new ground by targeting vascular anomalies with OKI-355. Vascular anomalies are a group of rare disorders characterized by abnormal blood vessel development, for which PIK3CA mutations are a primary driver. These conditions can cause disfigurement, pain, and life-threatening complications, and the patient population is considered largely underserved by current treatments.

Existing therapies are often localized, surgical, or palliative, failing to address the underlying genetic cause of the disease. OnKure believes OKI-355 has the potential to be a differentiated systemic chronic therapy, offering a targeted, long-term treatment option for patients who currently have few effective choices. This expansion into a rare disease indication highlights the broad potential of the company's selective inhibition platform.

Investor Confidence and Strategic Leadership

The success of the oversubscribed $150 million financing round is a powerful endorsement of OnKure's science and strategy. The participation of prominent specialist biotech investors—including new lead Access Biotechnology and existing partners like BVF Partners LP and RA Capital Management—demonstrates a deep belief in the technology's potential from some of the most discerning firms in the sector.

Further solidifying this partnership, Liam Ratcliffe, M.D., Ph.D., the Head of Biotechnology at Access Biotechnology, will join OnKure’s Board of Directors. Dr. Ratcliffe brings decades of experience from his time at Pfizer and as a managing director at New Leaf Venture Partners. His appointment is expected to provide invaluable strategic guidance as OnKure navigates the path toward clinical trials and potential commercialization.

“We are very pleased to welcome Liam to our Board of Directors,” said Andrew Phillips, Ph.D., OnKure’s Chairman of the Board. “Liam is a well-respected leader who brings a remarkable track record of accomplishment to our Board.”

With a fortified balance sheet ensuring operations into 2029 and a board strengthened by deep industry expertise, OnKure is positioned to execute its ambitious plan. The company is now focused on leveraging its powerful chemistry platform to bring its next-generation candidates to the clinic, with the goal of delivering medicines that offer meaningful improvements in efficacy and tolerability for patients with cancer and other serious diseases.